USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
US COVID-19 Vaccines and Therapeutics Tracker—Market Insights and Trends, H1 2021
Agnostic Vaccine Platform Technology Enhancing Future Growth Potential of Participants in the Value Chain
30-Apr-2021
North America
Tracker
K613-01-00-00-00
HC03412-NA-TC_25410
$2,450.00
Special Price $1,837.50 save 25 %
This study by Frost & Sullivan’s Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants. The US response to the pandemic has been disorganized and made worse with the politicization of vaccine approval and distribution, creating distrust and delaying the country’s vaccination program. Each state in the US has its own vaccination strategy and as such, state health department websites are critical sources of information on when, where, and how to get vaccines.
As of 31 March 2021, the US Food & Drug Administration granted Emergency Use Authorization to three vaccines manufactured respectively by Pfizer and BioNTech, Moderna, and Johnson & Johnson. Novavax and AstraZeneca vaccines are two other leading vaccine candidates expected to be approved for use in Q2 2021. Apart from vaccines, drugs are likely to play a critical role in treating individuals not responding to vaccines, not receiving vaccines, and who still contracted the virus despite vaccination.
Maintaining vaccine integrity through all stages of the supply chain requires never-before-seen levels of monitoring and coordination among stakeholders. Partnerships between input supply firms and distributors are as critical as collaborations between vaccine sponsors and contract manufacturers to scale up production for mass immunization. Key topics covered in the study include:
• Key COVID-19 vaccines and therapeutics analysis
• COVID-19 vaccines supply chain and distribution analysis
• Snapshot of the US vaccination strategy
• Prospective analysis of COVID-19 becoming endemic
Author: Surbhi Gupta
Growth Opportunities Fuel the Growth Pipeline Engine™
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top Three Strategic Imperatives on the US COVID-19 Vaccines and Therapeutics Market
H1 2021 US Key Tracking Metrics
Executive Summary
Executive Summary (continued)
Scope of Analysis
COVID-19 Vaccines Snapshot—Pipeline Analysis
COVID-19 Vaccines Snapshot—Vaccines Granted EUA
COVID-19 Vaccines Snapshot—Key Manufacturing Deals and Partnerships for the US Supply of Approved Vaccines
COVID-19 Vaccines Snapshot—Key Vaccine Candidates in Phase III
COVID-19 Therapeutics Snapshot—Current Global Treatments
COVID-19 Therapeutics Snapshot—Key Small Molecules in Phase III
COVID-19 Therapeutics Snapshot—Key mAbs in Phase III
COVID-19 Vaccines Manufacturing Supply Chain—Stages and Inputs
COVID-19 Vaccines Supply Chain—US Key Stakeholders
COVID-19 Vaccines Supply Chain from Factory to the Point of Use
US COVID-19 Vaccines Distribution Framework
Logistics Providers—Maintaining the Cold Chain to the Point of Use
Logistics Providers—Key Activities of Operation Warp Speed’s Logistics Partners
Central Distribution Hub—McKesson’s Role in Vaccines Distribution
Ancillary Supply Kits—Requisites for Different COVID-19 Vaccines
Scaling Up Syringes and Needles Manufacturing to Meet Vaccination Targets
US COVID-19 Vaccination Snapshot—By Vaccine Type
US COVID-19 Vaccination Snapshot—Administration Sites
US COVID-19 Vaccines Distribution Sites—Private Companies Fortifying Distribution Networks
US COVID-19 Vaccination Snapshot—Rollout in Key States
US COVID-19 Vaccination Snapshot—Successful Rollout Examples
Possible Factors of COVID-19 Becoming Endemic
Future of COVID-19 Vaccination—Seasonal Rollout Possibility
Growth Opportunity 1—Agnostic Vaccine Platform Technology for Emerging Virus Variants and Future Infectious Disease Outbreaks, 2021
Growth Opportunity 1—Agnostic Vaccine Platform Technology for Emerging Virus Variants and Future Infectious Disease Outbreaks, 2021 (continued)
Key Companies—Developing Next-generation COVID-19 Vaccines
Growth Opportunity 2—Precise Syringes and Adequate Dry Ice Supply for Effective Mass Vaccination, 2021
Growth Opportunity 2—Precise Syringes and Adequate Dry Ice Supply for Effective Mass Vaccination, 2021 (continued)
List of Exhibits
List of Exhibits (continued)
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-car...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Tracker |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Surbhi Gupta |
| Industries | Healthcare |
| WIP Number | K613-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,9562-B1,9568-B1,9611-B1,9627-B1 |